entertainment -WSS

entertainment

author：Wikipedia 2025-10-02 05:20:14 - browse：888

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： STAT Readout: Friday, Oct. 20 biotech updates

focus

hotspot

WSS

Why a market frenzy over new weight loss drugs defies logic

Study points to new risk in gene therapy death of Terry Horgan

2023 Nobel Prize in Medicine goes to Karikó and Weissman

RSV injection headlines need to be accurate for good uptake

STAT Readout Newsletter: Biotech news today

CRISPR base editing slashes cholesterol levels in monkeys

leisure time

entertainment

entertainment

Walensky prepares to leave CDC — and Congress — behind

Experts study whether long Covid risk adds up with each reinfection

The high cost of giving birth even with insurance

Medicare innovation center doesn’t save money, experts say

Moonlake's readout produced a cash windfall. Risks remain

Setback for rare diseases as Taysha Gene Therapies pulls back

Heart attack and stroke risk calculators need revising

CRISPR base editing slashes cholesterol levels in monkeys

How to save PrEP access — and even expand it

WHO recommends second malaria vaccine

focus

Medicare innovation center doesn’t save money, experts say

Is there really a nursing shortage in the U.S.?

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Smaller biotechs seek to piggyback on weight loss drug boom

New oral drug delivery patch is modeled after octopus tentacles

CZI to create biohub to build anti

entertainment

focus

hotspot

hotspot